Why medical device automation is accelerating
Three pressures are pushing device makers to automate in 2026. Tariff uncertainty and reshoring are raising labor and supply costs: a Section 232 investigation into medical device imports has been open since September 2025 (Federal Register). Skilled labor is scarce. And the regulatory framework has become friendlier to modern validation methods, with FDA’s Computer Software Assurance (CSA) guidance updated on February 3, 2026 (FDA).
The broader manufacturing data point in the same direction. Deloitte’s 2025 Smart Manufacturing Survey found 92% of manufacturers believe smart manufacturing will be the main driver of competitiveness over the next three years, with reported gains of up to 20% in production output, and 29% using AI or machine learning at the facility or network level (Deloitte). Device-specific trade press describes companies moving toward highly automated “dark factory” lines, though those reports rely mainly on company statements (Medical Technology).
Where automation is used in medical device companies
| Area | Examples | Regulatory touchpoint |
|---|---|---|
| Assembly and processing | Robotic assembly, automated molding, laser welding, automated packaging and sealing | Process validation (ISO 13485 clause 7.5.6) |
| Inspection and test | Machine vision, automated leak and functional testing, in-line metrology | Validation of the inspection method; acceptance activities |
| Labeling | Automated label printing, UDI verification, vision checks | §820.45 labeling and packaging controls |
| Production records | Manufacturing execution systems (MES), electronic device history records | Software validation; record controls (ISO 13485 clause 4.2.5) |
| Quality management | eQMS workflows for CAPA, complaints, change control, training | Software validation (ISO 13485 clause 4.1.6) |
| Document review | AI-assisted review of procedures, records and submissions | Risk-based assurance under CSA; human oversight |
What the regulations expect from automated processes
Validation of automated processes. ISO 13485 requires validation of processes whose output cannot be or is not verified by subsequent monitoring or measurement. In the QMSR final rule, FDA goes further, stating that “all processes require some degree of qualification, verification, or validation,” and that “manufacturers should not rely solely on inspection and testing” (Federal Register). An automated line therefore needs validated processes and validated equipment software, not just good final inspection.
Validation of software used in the QMS and production. ISO 13485 clause 4.1.6 requires validation of computer software used in the QMS, and clause 7.5.6 covers software used in production and service provision, both proportionate to risk. Under the QMSR these requirements now apply directly in the US.
Change control. Automation changes often: firmware updates, new vision recipes, robot program edits. Each change is a design or process change that needs evaluation, and FDA’s revised inspection program treats change control as one of six QMS areas it examines (FDA CP 7382.850).
Records and data integrity. Automated systems generate the records that prove product conformity. Records must be legible, retrievable and protected against unauthorized change, and electronic records remain subject to 21 CFR Part 11 where applicable.
Validating automation with Computer Software Assurance
FDA’s CSA guidance replaces the document-heavy approach of the 2002 General Principles of Software Validation for production and quality system software. Its scope explicitly includes automation: the risk framework applies to “automation tools (e.g., BOTS or automatic workflows), data analytic tools, artificial intelligence/machine learning tools” used in production or the QMS (FDA CSA guidance).
The guidance follows four steps:
- Identify the intended use. Is the software used directly in production or the QMS, or does it support those processes (for example, a tool that tracks training)?
- Determine the risk. A feature poses high process risk when its “failure to perform as intended may result in a quality problem” that foreseeably compromises safety (FDA).
- Select assurance activities. High-risk features get more rigorous, often scripted testing. For others, FDA says manufacturers may use unscripted methods such as scenario testing, error-guessing and exploratory testing.
- Establish the record. Keep enough evidence to show the software performs as intended, without generating paperwork for its own sake.
CSA also lets you rely on vendor work. Established purchasing controls for selecting and monitoring software vendors are listed as a consideration that can reduce assurance effort, which matters when you buy a commercial MES, vision system or eQMS rather than building one.
Example: risk-based assurance for an automated line
| Automated function | Process risk | Assurance approach |
|---|---|---|
| Vision system rejecting seal defects on sterile pouches | High: a miss could release a non-sterile device | Scripted challenge testing with known defects; full IQ/OQ/PQ |
| MES enforcing the correct work instruction version | High if it controls build steps | Scripted testing of version enforcement; negative tests |
| Robot cycle-time dashboard | Not high: no impact on product quality | Unscripted or exploratory testing; vendor documentation |
| Automated CAPA due-date reminders | Not high | Ad hoc testing; record of intended use |
A practical automation roadmap
- Map the process and its risks. Start from the process FMEA and the risk file. Automate where variability or manual error creates the most risk or cost.
- Write user requirements that include compliance needs. Include record content, audit trails, access control, labeling checks and alarm handling, not only throughput.
- Qualify the supplier. Assess the equipment or software vendor under your purchasing controls and capture what testing they already did.
- Validate in proportion to risk. Use CSA for software and full process validation where outputs are not fully verified.
- Plan for change. Define how recipe edits, firmware updates and model retraining will be evaluated, approved and revalidated.
- Monitor in production. Track false rejects, escapes, downtime and nonconformances, and feed them into data analysis and CAPA.
Medical device automation checklist
- Automation project linked to the risk file and process FMEA
- User requirements cover quality, records and data integrity, not just speed
- Vendor qualified and vendor test evidence reviewed
- Intended use and process risk determined for each software feature
- Assurance activities proportionate to risk and documented
- Process validation (IQ/OQ/PQ) complete where output is not fully verified
- Automated inspection validated with known-good and known-bad samples
- Labeling and UDI checks meet §820.45
- Change control covers recipes, firmware, robot programs and AI models
- Electronic records secure, attributable and retrievable
- Production data reviewed in data analysis and management review
Automate the documentation, too
Automated lines generate validation protocols, reports, change records and supplier files faster than teams can review them. AI document assessment can check those documents against ISO 13485, QMSR and your own procedures, flag gaps such as missing acceptance criteria or untested requirements, and cite the passage behind every finding, while people keep the decisions.
Run a sample regulatory document assessment on one validation package. AskDona shows the evidence; your engineers decide.
FAQ
Does FDA require validation of automated equipment? Yes. Processes whose output is not fully verified must be validated, and FDA states that “all processes require some degree of qualification, verification, or validation” (Federal Register).
What is Computer Software Assurance? FDA’s risk-based approach to establishing confidence in production and quality system software, which focuses testing on features with high process risk (FDA).
Does CSA apply to AI tools? Yes. The guidance names AI and machine learning tools used in production or the QMS within its scope (FDA).
Can we rely on vendor validation? Partly. Established purchasing controls over software vendors can reduce your assurance effort, but you remain responsible for confirming the software works for your intended use.
References
All pages opened and checked by October 13, 2026.
| Source | Type | Date | Used for |
|---|---|---|---|
| FDA: CSA guidance (page) | Regulator guidance | Feb 3, 2026 | CSA overview |
| FDA: CSA guidance (PDF) | Regulator guidance | Feb 3, 2026 | Scope, risk, testing methods |
| Federal Register: QMSR final rule | Regulation | Feb 2, 2024 | Process validation |
| FDA: CP 7382.850 | Regulator | Feb 2, 2026 | Change control area |
| Federal Register: Section 232 notice | Government | Sep 26, 2025 | Tariff investigation |
| Deloitte: 2025 Smart Manufacturing Survey | Consultancy survey | 2025 | Adoption data |
| Medical Technology: Dark factory shift | Trade press | Feb 2026 | Device examples (company claims) |